Heather Hilton
Family · Stuart, FLNPI 1275018731
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,033 and has fallen 87.6% since, to $129 in 2025.
Across 140 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$563
- Bristol Myers Squibb$202
- Astellas Pharma US Inc$192
- AstraZeneca$168
- Merck$168
- Pfizer$147
- plus $2K from 36 others
What the payments were for
- Food & beverage$2,78595%
- Education$1615%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 34 | $563 |
| Bristol Myers Squibb | 9 | $202 |
| Astellas Pharma US Inc | 4 | $192 |
| AstraZeneca | 7 | $168 |
| Merck | 9 | $168 |
| Pfizer | 8 | $147 |
| E.r. Squibb & Sons, L.L.C. | 1 | $124 |
| Daiichi Sankyo Inc. | 7 | $122 |
| Novartis | 5 | $105 |
| Lilly USA, LLC | 5 | $94 |
| Sanofi | 4 | $78 |
| AbbVie | 4 | $75 |
| Coherus Oncology, Inc. | 1 | $74 |
| Foundation Medicine, Inc. | 1 | $69 |
| Jazz Pharmaceuticals Inc. | 3 | $60 |
| Amgen | 4 | $59 |
| Bayer | 3 | $46 |
| Eisai Inc. | 2 | $44 |
| Mirati Therapeutics, Inc. | 2 | $37 |
| Taiho Oncology, Inc. | 2 | $35 |
| Sobi, Inc | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Puma Biotechnology, Inc. | 2 | $30 |
| Epizyme, Inc. | 2 | $30 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $28 |
| Incyte Corporation | 1 | $27 |
| Array Biopharma Inc | 1 | $25 |
| Seagen Inc. | 1 | $25 |
| Octapharma USA, Inc. | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $23 |
| Beigene USA, Inc. | 1 | $23 |
| Genmab U.S., Inc. | 1 | $21 |
| Heron Therapeutics, Inc. | 1 | $21 |
| Accord Healthcare, Inc. | 1 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Dova Pharmaceuticals | 1 | $17 |
| Dendreon Pharmaceuticals LLC | 1 | $16 |
| Morphosys, US Inc. | 1 | $15 |
| Novocure Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Tolmar Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reblozyl$124
How this compares
$2,946 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 14 | $683 |
| Prochlorperazine Maleate | 11 | $238 |
Paid to pharmacies, not to this prescriber.
Other family in Stuart
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.